Key regions: China, Europe, Australia, United States, Germany
The Other Pharmaceuticals market in Mozambique has been experiencing steady growth in recent years.
Customer preferences: Mozambique's population is largely rural, with limited access to healthcare facilities. As a result, there is a high demand for affordable and accessible healthcare products, including pharmaceuticals. Due to the limited availability of prescription drugs, many Mozambicans turn to over-the-counter (OTC) medicines for treatment of common ailments such as headaches, colds, and flu.
Trends in the market: The Other Pharmaceuticals market in Mozambique is largely driven by the demand for OTC medicines. This demand is expected to continue to grow as the country's population increases and access to healthcare facilities remains limited. In addition, there is a growing trend towards the use of traditional medicine in Mozambique, which is expected to further boost the Other Pharmaceuticals market.
Local special circumstances: Mozambique is a low-income country with a high burden of disease, including HIV/AIDS, malaria, and tuberculosis. The government has been working to improve access to healthcare services, but the country still faces significant challenges in terms of healthcare infrastructure and funding. As a result, the private sector plays a significant role in the provision of healthcare services and pharmaceuticals in Mozambique.
Underlying macroeconomic factors: Mozambique's economy has been growing steadily in recent years, driven by natural resource exports and foreign investment. However, the country still faces significant challenges in terms of poverty, inequality, and corruption. The government has been working to address these issues, but progress has been slow. The pharmaceutical industry in Mozambique is heavily regulated, which can make it difficult for foreign companies to enter the market. However, the government has been working to improve the regulatory environment in order to attract more investment in the sector.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
